Denmark's Novo Nordisk has agreed to pay $70 million ... semaglutide in phase 3 in combination with drugs from Gilead, a long-acting FGF21 analogue in phase 2, and early-stage candidates partnered ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

The drug has also been evaluated in adults and adolescents. Following the positive data, Novo Nordisk expects to make its Mim8 regulatory submission in 2025. Haemophilia A is a rare blood disorder ...

(Image Credits: PIxabay) Novo Nordisk on Wednesday announced that it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next ...

Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential successor to Wegovy (semaglutide), as the company aims to quell ...

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued a forecast for full-year 2025 results that topped analysts ...

Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment. Never before was there a drug that actually worked for weight loss.

Patients will pay no more than $35 a month. Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 diabetes and chronic kidney ...

Novo Nordisk and Eli Lilly have asked the federal government to list their blockbuster weight-loss drugs on the Pharmaceutical Benefits Scheme, arguing funding the treatment will reduce a costly ...

GLP-1 drugs like Ozempic require injections, severely limiting their adoption. While Novo Nordisk owns the market for now, a pill-based GLP-1 would be a game changer. The company is in a race with ...